Interleukin-35 in immune-related diseases: protection or destruction

Junfeng Zhang,Yunsheng Zhang,Qingpeng Wang,Chunlei Li,Hongxin Deng,Chuanping Si,Huabao Xiong

DOI: https://doi.org/10.1111/imm.13044

2019-01-01

Immunology

Abstract:Interleukin-35 (IL-35) is a recently identified heterodimeric cytokine in the IL-12 family. It consists of an IL-12 subunit chain (P35) and IL-27 subunit Epstein-Barr virus-induced gene 3 (EBI3) chain. Unlike the other IL-12 family members, it signals through four unconventional receptors: IL-12R2-IL-27R, IL-12R2-IL-12R2, IL-12R2-GP130, and GP130-GP130. Interleukin-35 signaling is mainly carried out through the signal transducer and activator of transcription family of proteins. It is secreted not only by regulatory T (Treg) cells, but also by CD8(+) Treg cells, activated dendritic cells and regulatory B cells. It exhibits immunosuppressive functions distinct from those of other members of the IL-12 family; these are mediated primarily by the inhibition of T helper type 17 cell differentiation and promotion of Treg cell proliferation. Interleukin-35 plays a critical role in several immune-associated diseases, such as autoimmune diseases and viral and bacterial infections, as well as in tumors. In this review, we summarize the structure and function of IL-35, describe its role in immune-related disorders, and discuss the mechanisms by which it regulates the development and progression of diseases, including inflammatory bowel disease, collagen-induced arthritis, allergic airway disease, hepatitis, and tumors. The recent research on IL-35, combined with improved techniques of studying receptors and signal transduction pathways, allows for consideration of IL-35 as a novel immunotherapy target.